Replimune Group, Inc. (REPL)
19.07
-0.16
(-0.83%)
USD |
NASDAQ |
Nov 20, 16:00
19.07
0.00 (0.00%)
After-Hours: 20:00
Replimune Group Research and Development Expense (TTM) : 188.02M for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 188.02M |
| June 30, 2026 | 211.67M |
| March 31, 2026 | 220.36M |
| December 31, 2025 | 222.70M |
| September 30, 2025 | 218.21M |
| June 30, 2025 | 204.42M |
| March 31, 2025 | 190.17M |
| December 31, 2024 | 178.89M |
| September 30, 2024 | 173.78M |
| June 30, 2024 | 179.46M |
| March 31, 2024 | 176.88M |
| December 31, 2023 | 172.47M |
| September 30, 2023 | 159.47M |
| June 30, 2023 | 138.73M |
| March 31, 2023 | 127.71M |
| December 31, 2022 | 111.02M |
| September 30, 2022 | 100.32M |
| June 30, 2022 | 91.63M |
| Date | Value |
|---|---|
| March 31, 2022 | 80.64M |
| December 31, 2021 | 75.03M |
| September 30, 2021 | 69.81M |
| June 30, 2021 | 63.99M |
| March 31, 2021 | 57.49M |
| December 31, 2020 | 54.72M |
| September 30, 2020 | 51.80M |
| June 30, 2020 | 45.68M |
| March 31, 2020 | 40.81M |
| December 31, 2019 | 32.47M |
| September 30, 2019 | 28.90M |
| June 30, 2019 | 25.69M |
| March 31, 2019 | 22.17M |
| December 31, 2018 | 21.26M |
| September 30, 2018 | 16.97M |
| June 30, 2018 | 15.16M |
| March 31, 2018 | 13.52M |
| December 31, 2017 | 11.50M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| PepGen Inc. | 52.70M |
| Oncolytics Biotech, Inc. | 13.18M |
| Sangamo Therapeutics, Inc. | 113.79M |
| Sarepta Therapeutics, Inc. | 647.26M |
| Anixa Biosciences, Inc. | 4.828M |